SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-18-010334
Filing Date
2018-08-02
Accepted
2018-08-02 16:05:06
Documents
54
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q adms10q06302018.htm 10-Q 1017842
2 EXHIBIT 10.1 admsq210q2018ex101.htm EX-10.1 14507
3 EXHIBIT 31.1 admsq210q2018ex311.htm EX-31.1 14293
4 EXHIBIT 31.2 admsq210q2018ex312.htm EX-31.2 14405
5 EXHIBIT 32.1 admsq210q2018ex321.htm EX-32.1 9282
  Complete submission text file 0001628280-18-010334.txt   3999260

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT adms-20180630.xml EX-101.INS 724840
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20180630.xsd EX-101.SCH 30572
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20180630_cal.xml EX-101.CAL 53766
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20180630_def.xml EX-101.DEF 132885
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20180630_lab.xml EX-101.LAB 390846
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20180630_pre.xml EX-101.PRE 218504
Mailing Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36399 | Film No.: 18988220
SIC: 2834 Pharmaceutical Preparations